575 related articles for article (PubMed ID: 19019811)
1. Practical management of dyslipidemia with elevated lipoprotein(a).
Riche DM; East HE; Priest HM
J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
[TBL] [Abstract][Full Text] [Related]
5. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
[TBL] [Abstract][Full Text] [Related]
6. Effects of Extended-Release Niacin on Quartile Lp-PLA
Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
[TBL] [Abstract][Full Text] [Related]
7. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
Nozue T; Michishita I; Mizuguchi I
J Atheroscler Thromb; 2010 Feb; 17(1):37-44. PubMed ID: 20075599
[TBL] [Abstract][Full Text] [Related]
8. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
McKenney JM; Jones PH; Bays HE; Knopp RH; Kashyap ML; Ruoff GE; McGovern ME
Atherosclerosis; 2007 Jun; 192(2):432-7. PubMed ID: 17239888
[TBL] [Abstract][Full Text] [Related]
13. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
Jelesoff NE; Ballantyne CM; Xydakis AM; Chiou P; Jones PH; Guyton JR
Endocr Pract; 2006; 12(2):159-64. PubMed ID: 16690463
[TBL] [Abstract][Full Text] [Related]
15. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
17. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
18. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy in dyslipidemia: where are we now?
Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
[TBL] [Abstract][Full Text] [Related]
20. Important considerations for treatment with dietary supplement versus prescription niacin products.
Backes JM; Padley RJ; Moriarty PM
Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
